These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

418 related articles for article (PubMed ID: 30258084)

  • 1. Comparison of immunogenicity and vaccine efficacy between heat-shock proteins, HSP70 and GrpE, in the DnaK operon of Mycobacterium tuberculosis.
    Kim WS; Kim JS; Kim HM; Kwon KW; Eum SY; Shin SJ
    Sci Rep; 2018 Sep; 8(1):14411. PubMed ID: 30258084
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Kim WS; Jung ID; Kim JS; Kim HM; Kwon KW; Park YM; Shin SJ
    Front Cell Infect Microbiol; 2018; 8():95. PubMed ID: 29637049
    [No Abstract]   [Full Text] [Related]  

  • 3. Novel vaccine potential of Rv3131, a DosR regulon-encoded putative nitroreductase, against hyper-virulent Mycobacterium tuberculosis strain K.
    Kwon KW; Kim WS; Kim H; Han SJ; Hahn MY; Lee JS; Nam KT; Cho SN; Shin SJ
    Sci Rep; 2017 Mar; 7():44151. PubMed ID: 28272457
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mycobacterium tuberculosis Rv3628 drives Th1-type T cell immunity via TLR2-mediated activation of dendritic cells and displays vaccine potential against the hyper-virulent Beijing K strain.
    Kim WS; Kim JS; Cha SB; Kim H; Kwon KW; Kim SJ; Han SJ; Choi SY; Cho SN; Park JH; Shin SJ
    Oncotarget; 2016 May; 7(18):24962-82. PubMed ID: 27097115
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccine efficacy of a
    Kwon KW; Choi HH; Han SJ; Kim JS; Kim WS; Kim H; Kim LH; Kang SM; Park J; Shin SJ
    FASEB J; 2019 May; 33(5):6483-6496. PubMed ID: 30753099
    [No Abstract]   [Full Text] [Related]  

  • 6. Immunogenicity and Vaccine Potential of InsB, an ESAT-6-Like Antigen Identified in the Highly Virulent
    Kim WS; Kim H; Kwon KW; Cho SN; Shin SJ
    Front Microbiol; 2019; 10():220. PubMed ID: 30809214
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic efficacy of a tuberculosis DNA vaccine encoding heat shock protein 65 of Mycobacterium tuberculosis and the human interleukin 2 fusion gene.
    Changhong S; Hai Z; Limei W; Jiaze A; Li X; Tingfen Z; Zhikai X; Yong Z
    Tuberculosis (Edinb); 2009 Jan; 89(1):54-61. PubMed ID: 19056317
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Clemmensen HS; Dube JY; McIntosh F; Rosenkrands I; Jungersen G; Aagaard C; Andersen P; Behr MA; Mortensen R
    mBio; 2021 Apr; 12(2):. PubMed ID: 33879592
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of human T cell antigens for the development of vaccines against Mycobacterium tuberculosis.
    Bertholet S; Ireton GC; Kahn M; Guderian J; Mohamath R; Stride N; Laughlin EM; Baldwin SL; Vedvick TS; Coler RN; Reed SG
    J Immunol; 2008 Dec; 181(11):7948-57. PubMed ID: 19017986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity and protective efficacy of a tuberculosis DNA vaccine expressing a fusion protein of Ag85B-Esat6-HspX in mice.
    Yuan W; Dong N; Zhang L; Liu J; Lin S; Xiang Z; Qiao H; Tong W; Qin C
    Vaccine; 2012 Mar; 30(14):2490-7. PubMed ID: 21704108
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pulmonary immunity and durable protection induced by the ID93/GLA-SE vaccine candidate against the hyper-virulent Korean Beijing Mycobacterium tuberculosis strain K.
    Cha SB; Kim WS; Kim JS; Kim H; Kwon KW; Han SJ; Cho SN; Coler RN; Reed SG; Shin SJ
    Vaccine; 2016 Apr; 34(19):2179-87. PubMed ID: 27005808
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protective Vaccine Efficacy of the Complete Form of PPE39 Protein from Mycobacterium tuberculosis Beijing/K Strain in Mice.
    Kim A; Hur YG; Gu S; Cho SN
    Clin Vaccine Immunol; 2017 Nov; 24(11):. PubMed ID: 28877927
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cloning, expression, and immunogenicity of novel fusion protein of Mycobacterium tuberculosis based on ESAT-6 and truncated C-terminal fragment of HSP70.
    Tebianian M; Hoseini AZ; Ebrahimi SM; Memarnejadian A; Mokarram AR; Mahdavi M; Sohrabi N; Taghizadeh M
    Biologicals; 2011 May; 39(3):143-8. PubMed ID: 21388826
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incorporation of immunostimulatory motifs in the transcribed region of a plasmid DNA vaccine enhances Th1 immune responses and therapeutic effect against Mycobacterium tuberculosis in mice.
    Wu J; Ma H; Qu Q; Zhou WJ; Luo YP; Thangaraj H; Lowrie DB; Fan XY
    Vaccine; 2011 Oct; 29(44):7624-30. PubMed ID: 21856352
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protection against Mycobacterium tuberculosis infection offered by a new multistage subunit vaccine correlates with increased number of IFN-γ+ IL-2+ CD4+ and IFN-γ+ CD8+ T cells.
    Wang X; Zhang J; Liang J; Zhang Y; Teng X; Yuan X; Fan X
    PLoS One; 2015; 10(3):e0122560. PubMed ID: 25822536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel vaccine strategy to induce mycobacterial antigen-specific Th1 responses by utilizing the C-terminal domain of heat shock protein 70.
    Uto T; Tsujimura K; Uchijima M; Seto S; Nagata T; Suda T; Chida K; Nakamura H; Koide Y
    FEMS Immunol Med Microbiol; 2011 Mar; 61(2):189-96. PubMed ID: 21204994
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fused Mycobacterium tuberculosis multi-stage immunogens with an Fc-delivery system as a promising approach for the development of a tuberculosis vaccine.
    Mosavat A; Soleimanpour S; Farsiani H; Sadeghian H; Ghazvini K; Sankian M; Jamehdar SA; Rezaee SA
    Infect Genet Evol; 2016 Apr; 39():163-172. PubMed ID: 26835592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The ΔfbpA attenuated candidate vaccine from Mycobacterium tuberculosis, H37Rv primes for a stronger T-bet dependent Th1 immunity in mice.
    Roche CM; Smith A; Lindsey DR; Meher A; Schluns K; Arora A; Armitige LY; Jagannath C
    Tuberculosis (Edinb); 2011 Dec; 91 Suppl 1():S96-104. PubMed ID: 22082615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mycobacterium tuberculosis multistage antigens confer comprehensive protection against pre- and post-exposure infections by driving Th1-type T cell immunity.
    Ma J; Tian M; Fan X; Yu Q; Jing Y; Wang W; Li L; Zhou Z
    Oncotarget; 2016 Sep; 7(39):63804-63815. PubMed ID: 27566581
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mucosal delivery of antigen-coated nanoparticles to lungs confers protective immunity against tuberculosis infection in mice.
    Stylianou E; Diogo GR; Pepponi I; van Dolleweerd C; Arias MA; Locht C; Rider CC; Sibley L; Cutting SM; Loxley A; Ma JK; Reljic R
    Eur J Immunol; 2014 Feb; 44(2):440-9. PubMed ID: 24214530
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.